Patients’ characteristics from the infliximab trial and the etanercept trial, and the combined trial group
| Characteristics | Infliximab trial (n = 69) | Etanercept trial (n = 30) | Total trial group (n = 99) |
|---|---|---|---|
| *Indicates advanced radiological changes of the spine (syndesmophytes of three vertebrae or more). | |||
| Male sex, No (%) | 45 (65) | 22 (73) | 67 (68) |
| Age (years), mean (SD) | 39.6 (8.6) | 35.6 (9.1) | 38,4 (8.9) |
| Disease duration (years), mean (SD) | 15.6 (8.8) | 13.03 (8.6) | 14.8 (8.8) |
| HLA-B27 positive, No (%) | 61 (88) | 27 (90) | 88 (89) |
| BASDAI | 6.4 (1.3) | 6.6 (1.1) | 6.4 (1.2) |
| BASFI | 5.3 (2) | 5.7 (2.1) | 5.4 (2) |
| CRP (mg/l), mean (SD) | 27.3 (25.7) | 21.5 (18.5) | 25.5 (23.8) |
| Peripheral arthritis, mean (SD) | 41 (59.4) | 19 (63.3) | 60 (60.6) |
| Enthesitis, mean (SD) | 37 (53.6) | 19 (63.3) | 56 (56.6) |
| Ankylosis of sacroiliac joints (grade 4), mean (SD) | 23 (33.3) | 11 (36.7) | 34 (34.39 |
| BASRI lumbar spine (3–4)*, mean (SD) | 14 (20.6) | 9 (31.0) | 23 (23.7) |
| BASRI cervical spine (3–4)*, mean (SD) | 17 (27.0) | 3 (11.1) | 20 (22.2) |
| BASDAI 50 response, No (%) | 36 (52) | 19 (63) | 55 (56) |
| ASAS 40 response, No (%) | 39 (57) | 19 (63) | 58 (59) |